全文获取类型
收费全文 | 4164篇 |
免费 | 286篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 42篇 |
儿科学 | 89篇 |
妇产科学 | 85篇 |
基础医学 | 535篇 |
口腔科学 | 112篇 |
临床医学 | 330篇 |
内科学 | 881篇 |
皮肤病学 | 85篇 |
神经病学 | 673篇 |
特种医学 | 96篇 |
外科学 | 744篇 |
综合类 | 16篇 |
预防医学 | 200篇 |
眼科学 | 40篇 |
药学 | 190篇 |
中国医学 | 2篇 |
肿瘤学 | 351篇 |
出版年
2024年 | 8篇 |
2023年 | 38篇 |
2022年 | 82篇 |
2021年 | 150篇 |
2020年 | 70篇 |
2019年 | 117篇 |
2018年 | 153篇 |
2017年 | 120篇 |
2016年 | 101篇 |
2015年 | 126篇 |
2014年 | 174篇 |
2013年 | 179篇 |
2012年 | 332篇 |
2011年 | 342篇 |
2010年 | 203篇 |
2009年 | 142篇 |
2008年 | 223篇 |
2007年 | 220篇 |
2006年 | 199篇 |
2005年 | 213篇 |
2004年 | 205篇 |
2003年 | 170篇 |
2002年 | 144篇 |
2001年 | 49篇 |
2000年 | 51篇 |
1999年 | 68篇 |
1998年 | 39篇 |
1997年 | 26篇 |
1996年 | 24篇 |
1995年 | 31篇 |
1994年 | 21篇 |
1993年 | 13篇 |
1992年 | 37篇 |
1991年 | 31篇 |
1990年 | 29篇 |
1989年 | 33篇 |
1988年 | 28篇 |
1987年 | 29篇 |
1986年 | 24篇 |
1985年 | 12篇 |
1984年 | 26篇 |
1983年 | 21篇 |
1982年 | 10篇 |
1980年 | 8篇 |
1979年 | 16篇 |
1978年 | 15篇 |
1977年 | 10篇 |
1975年 | 10篇 |
1974年 | 13篇 |
1969年 | 9篇 |
排序方式: 共有4471条查询结果,搜索用时 15 毫秒
61.
62.
Fulvia Milena Cribi Roberta Erra Lorenza Pugni Carlota Rubio-Perez Lidia Alonso Sara Simonetti Giorgio Alberto Croci Garazi Serna Andrea Ronchi Carlo Pietrasanta Giovanna Lunghi Anna Maria Fagnani Maria Piana Matthias Matter Alexandar Tzankov Luigi Terracciano Andres Anton Enrico Ferrazzi Stefano Ferrero Enrico Iurlaro Joan Seoane Paolo Nuciforo 《The Journal of clinical investigation》2021,131(6)
63.
Mutations in leucine rich repeat kinase 2 (LRRK2) are a major cause of familial Parkinson's disease (PD) and a risk factor for its sporadic form. LRRK2 hyperactivity has also been reported in sporadic PD, making LRRK2 an appealing target for PD small-molecule therapeutics. At a cellular level, increasing evidence suggests that LRRK2 regulates membrane trafficking. Under some conditions LRRK2 also associates with microtubules, the cellular tracks used by dynein and kinesin motors to move membranes. At a structural level, however, relatively little was known about LRRK2. An important step toward bridging this gap took place last year with the publication of structures of LRRK2's cytosolic and microtubule-bound forms. Here, we review the main findings from these studies and discuss what we see as the major challenges going forward with a focus on areas that will require structural information. We also introduce the structural techniques—cryo-electron microscopy and cryo-electron tomography—that were instrumental to solving the structures of LRRK2. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society 相似文献
64.
Marco Romano Monica Sen Cristiano Scottà Rowa Y. Alhabbab Andres Rico-Armada Robert I. Lechler Michael Burch Giovanna Lombardi 《European journal of immunology》2021,51(8):2086-2092
Regulatory T-cells (Tregs) are a subset of T cells generated in the thymus with intrinsic immunosuppressive properties. Phase I clinical trials have shown safety and feasibility of Treg infusion to promote immune tolerance and new studies are ongoing to evaluate their efficacy. During heart transplantation, thymic tissue is routinely discarded providing an attractive source of Tregs. In this study, we developed a GMP-compatible protocol for expanding sorted thymus-derived CD3+CD4+CD25+CD127– (Tregs) as well as CD3+CD4+CD25+CD127–CD45RA+ (RA+Tregs) cells. We aimed to understand whether thymic RA+Tregs can be isolated and expanded offering an advantage in terms of stability as it has been previously shown for circulating adult CD45RA+ Tregs. We show that both Tregs and RA+Tregs could be expanded in large numbers and the presence of rapamycin is essential to inhibit the growth of IFN-γ producing cells. High levels of FOXP3, CTLA4, and CD25 expression, demethylation of the FOXP3 promoter, and high suppressive ability were found with no differences between Tregs and RA+Tregs. After freezing and thawing, all Treg preparations maintained their suppressive ability, stability, as well as CD25 and FOXP3 expression. The number of thymic Tregs that could be isolated with our protocol, their fold expansion, and functional characteristics allow the clinical application of this cell population to promote tolerance in pediatric heart transplant patients. 相似文献
65.
de Siqueira Fabiana Suelen Figueredo Hilgemberg Bruna Araujo Lucila Cristina Rodrigues Hass Viviane Bandeca Matheus Coelho Gomes João Carlos Reis Alessandra Loguercio Alessandro D Cardenas Andres Felipe Millan 《Clinical oral investigations》2020,24(2):809-822
Clinical Oral Investigations - The aim of this study was to investigate the effects of collagen cross-linking agents on nanomechanical and bonding properties of eroded dentin (ED), 24 h... 相似文献
66.
67.
Clathrin-mediated endocytosis is required for compensatory regulation of GLR-1 glutamate receptors after activity blockade 下载免费PDF全文
Grunwald ME Mellem JE Strutz N Maricq AV Kaplan JM 《Proceedings of the National Academy of Sciences of the United States of America》2004,101(9):3190-3195
Chronic changes in neural activity trigger a variety of compensatory homeostatic mechanisms by which neurons maintain a normal level of synaptic input. Here we show that chronic activity blockade triggers a compensatory change in the abundance of GLR-1, a Caenorhabditis elegans glutamate receptor. In mutants lacking a voltage-dependent calcium channel (unc-2) or a vesicular glutamate transporter (VGLUT; eat-4), the abundance of GLR-1 in the ventral nerve cord was increased. Similarly, the amplitude of glutamate-evoked currents in ventral cord interneurons was increased in eat-4 VGLUT mutants compared with wild-type controls. The effects of eat-4 VGLUT mutations on GLR-1 abundance in the ventral cord were eliminated in double mutants lacking both the clathrin adaptin protein unc-11 AP180 and eat-4 VGLUT. In contrast, mutations that decreased ubiquitination of GLR-1 did not prevent increased ventral cord abundance of GLR-1 in eat-4 VGLUT mutants. Taken together, our results suggest that GLR-1 is regulated in a homeostatic manner and that this effect depends on clathrin-mediated endocytosis but does not require ubiquitination of GLR-1. 相似文献
68.
Victor Alfonso Jimenez Diaz Antonio Tello-Montoliu Raul Moreno Ignacio Cruz Gonzalez Jose Antonio Baz Alonso Rafael Romaguera Eduardo Molina Navarro Pablo Juan Salvadores Emilio Paredes Galan Antonio De Miguel Castro Guillermo Bastos Fernandez Alberto Ortiz Saez Saleta Fernandez Barbeira Sergio Raposeiras Roubin Juan Ocampo Miguez Antonio Serra Peñaranda Mariano Valdes Chavarri Angel Cequier Fillat Andres Iñiguez Romo 《JACC: Cardiovascular Interventions》2019,12(1):22-32
Objectives
The REAC-TAVI (Assessment of platelet REACtivity after Transcatheter Aortic Valve Implantation) trial enrolled patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) pre-treated with aspirin + clopidogrel, aimed to compare the efficacy of clopidogrel and ticagrelor in suppressing high platelet reactivity (HPR) after TAVI.Background
Current recommendations support short-term use of aspirin + clopidogrel for patients with severe AS undergoing TAVR despite the lack of compelling evidence.Methods
This was a prospective, randomized, multicenter investigation. Platelet reactivity was measured at 6 different time points with the VerifyNow assay (Accriva Diagnostics, San Diego, California). HPR was defined as (P2Y12 reaction units (PRU) ≥208. Patients with HPR before TAVR were randomized to either aspirin + ticagrelor or aspirin + clopidogrel for 3 months. Patients without HPR continued with aspirin + clopidogrel (registry cohort). The primary endpoint was non-HPR status (PRU <208) in ≥70% of patients treated with ticagrelor at 90 days post-TAVR.Results
A total of 68 patients were included. Of these, 48 (71%) had HPR (PRU 273 ± 09) and were randomized to aspirin + ticagrelor (n = 24, PRU 277 ± 08) or continued with aspirin + clopidogrel (n = 24, PRU 269 ± 49). The remaining 20 patients (29%) without HPR (PRU 133 ± 12) were included in the registry. Overall, platelet reactivity across all the study time points after TAVR was lower in patients randomized to ticagrelor compared with those treated with clopidogrel, including those enrolled in the registry (p < 0.001). The primary endpoint was achieved in 100% of patients with ticagrelor compared with 21% with clopidogrel (p < 0.001). Interestingly, 33% of clopidogrel responder patients at baseline developed HPR status during the first month after TAVR.Conclusions
HPR to clopidogrel is present in a considerable number of patients with AS undergoing TAVR. Ticagrelor achieves a better and faster effect, providing sustained suppression of HPR to these patients. (Platelet Reactivity After TAVI: A Multicenter Pilot Study [REAC-TAVI]; NCT02224066) 相似文献69.
70.